• EMR report projects that North America is likely to be fastest, largest marketplace for cannabis beverages
• Cannabis beverage industry projected to grow at CAGR of 48% in the next five years, reaching an anticipated $12.7 billion by 2026
• BevCanna manufactures its own beverage product lines, offers white-label services to companies looking for the highest-quality products available

North America will be a leader in the global cannabis beverage market, according to a recent Expert Market Research (“EMR”) report (https://ibn.fm/wtV1O). This projection bodes well for BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), a diversified health & wellness beverage and natural products company developing and manufacturing a range of alkaline, plant-based and cannabinoid beverages and supplements for both in-house brands and white-label clients. “North America is likely to be the fastest and largest marketplace for cannabis beverages,” the EMR report stated. “The legalization of cannabis for medical, therapeutic and recreational purposes is driving the growth of the market. In 2018, Canada legalized the utilization of marijuana for recreational and medical purposes. Various states in the U.S. have made the addition of cannabis infusion legal in food and beverages. This factor is predicted to spice up the expansion of the cannabis food and beverage market in North America.” EMR went on to note that worldwide, the cannabis beverage industry is expected to grow at a CAGR of 48% in the next five years, reaching an anticipated $12.7 billion by 2026. The report noted that increasing demand for wellness beverages is expected to drive the expansion of the cannabis beverages industry. Other drivers behind the market growth include the lower sugar content of the product, the presence of consistently dosed amount of cannabis for consumption, the legalization of marijuana consumption for medical and recreational purposes in many countries, and the growing consumer interest in cannabis edibles. “Cannabis consumers are shifting their interest from smoking cannabis to other ways, like beverages, tinctures, chocolates, and other edibles,” the report noted. “Consumers are willing to consume concentrated and cannabis-infused products, which successively is anticipated to support the market growth. Cannabis beverages are predicted to exchange other marijuana-infused consumables, like chocolates, cookies, brownies, and confectionaries like gummies and candies which are considered to be not healthy. This factor is predicted to spice up the demand for cannabis drinks over the forecasted period.” Ideally situated in this booming space, BevCanna is in a position to leverage its state-of-the-art facilities and expertise to manufacture its own beverage product lines and to provide white label solutions to a growing list of third-party companies. For more information, visit the company’s website at www.BevCanna.com. NOTE TO INVESTORS: The latest news and updates relating to BVNNF are available in the company’s newsroom at http://ibn.fm/BVNNF

• The growing plant-based consumer market one-stop shopping solution PlantX Life announced its most recent Q1 financials on Aug. 30
• The financial statement notes revenue growth of $3.95 million YOY (Canadian) as part of PlantX’s drive to build a number of verticals to support its one-stop-     shop mission since the company acquired PlantX Living in a reverse takeover in August 2020
• PlantX Life also improved on the previous quarter’s 23 percent gross margin to achieve a gross margin of 28 percent
• The company is expanding from its flagship store in Squamish, British Columbia to open similar stores in Southern California and Israel with a significant e-commerce operation seeking to educate and provide a wide variety of products for the plant-based community

Canadian e-commerce and plant-based community builder PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) is celebrating reports of its growing revenues and operational foothold following the announcement of its Q1 financial statement’s filing. The Vancouver, British Columbia-based company is developing a one-stop shopping experience for the plant-based community, simultaneously working to educate consumers about the virtues of plant-based living and help develop a cohesive coterie of like-minded food enthusiasts. PlantX Life’s interim unaudited condensed consolidated financial results for the three months ended June 30 note the company generated gross revenue of more than $4 million (Canadian), which was an increase of $3.95 million YOY (https://ibn.fm/vN7LU). During the past year, the company has undergone a period of rapid vertical building as part of its mis sion to grow a model similar to e-commerce giant Amazon’s but devoted to plant-based consumer interests. PlantX sells more than 5,000 products in line with its mission and plans to expand its offerings to include cosmetics, clothing, and its own water brand. While e-commerce is a significant part of its operations, the company maintains a flagship storefront in Squamish, British Columbia and is establishing additional physical stores in San Diego, California and Tel Aviv in the state of Israel to serve those nationalities (https://ibn.fm/bXyvs). According to the financial statement, the company achieved a gross margin of 28 percent for the quarter, compared to 23 percent during the previous quarter. As of June 30, PlantX had working capital of nearly $15 million, inclusive of $13.5 million in cash. “PlantX continues to invest its efforts and resources strategically to grow and meet the demand for our plant-based products,” founder Sean Dollinger stated. “It is encouraging to see the impact of our work. We are more committed than ever to continue building our business by executing on our mission and expansion goals.” Those investments include the acquisition of PlantX Living Inc. in a reverse takeover completed Aug. 5, 2020; the acquisition of Bloombox Club Ltd. completed Nov. 6; the acquisition of Score Enterprises Ltd. completed Jan. 7 of this year; the acquisition of Little West LLC completed May 10; the acquisition of all of the issued and outstanding membership interests of MK Cuisine Global LLC’s Plant-Based Deli LLC completed on May 27; and the acquisition of certain assets of LIV Marketplace LLC completed June 25, according to the company management’s accompanying discussion and analysis found on its SEDAR profile (https://ibn.fm/wE4GG). Bloombox is a service that hand-delivers locally grown plants and gardening supplies to consumers. Score Enterprises operated the Squamish restaurant location’s related operations that became the company’s flagship store. Little West LLC is a privately owned, California-based cold-pressed juice company. Deli LLC, also known as New Deli, is a sustainable and plant-based retail store in Venice Beach, Calif. LIV Marketplace, also part of the New Deli operation, is the San Diego, Calif., retail partner     responsible for the fulfillment of PlantX’s online product distribution within the United States. The San Diego store will open in September, and PlantX announced July 28 that its XFood delivery service in Southern California will use a ghost kitchen in central Los Angeles as part of an operation modeled after its food delivery services in British Columbia. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• Market report projects global functional beverages market will increase from $125 billion in 2020 to $216 billion by 2028
• A functional beverage is a nonalcoholic beverage formulated to have an added purpose
• The Happy Company’s Happy Coffees and nootropic beverages are developed to assist with weight loss, energy, focus, happiness and more

The global functional beverages market is projected to see consistent growth in the next several years, according to a recent Fior Market report, which forecast an increase from $125 billion in 2020 to an estimated $216 billion by 2028 (https://ibn.fm/iqwWA). This growth bodes well for Sharing Services Global (OTCQB: SHRG) and its subsidiary the Happy Co., which offers a line of Happy Coffees along with other nootropic beverages. “The functional drinks industry consists of sales of functional beverages by nonalcoholic beverage producers (organizations, individual dealers and partnerships),” the Fior report stated. “A functional beverage is a nonalcoholic beverage that has been formulated to have an added purpose, usually in the form of a health aid or performance enhancer. Minerals, vitamins, probiotics, dietary fibers and added fruits are among the nontraditional ingredients used in functional drinks.” The report noted that factors driving the market are increased demand for enhanced beverage products, growing consumer awareness of health, and key players in the industry focusing on innovation and development. “To aid the growth of the functional drinks industry, major players are pursuing numerous innovations such as the introduction of new brands, the opening of new research and development centers, and the construction of new plants,” noted the report. Drinks formulated to increase energy and assist with weight loss are among those impacting the market, with the energy drinks segment dominating the market and holding the largest market share of 20.9% in the year 2020,” reported Fior. “North America currently has the highest market share in the functional beverage market. It is predicted to retain its dominance for the duration of the forecasted period.” The Happy Company’s Happy Coffees and nootropic beverages are carefully formulated to assist with weight loss, energy (without the caffeine), focus, happiness and more (https://ibn.fm/D9mzF). “Nootropicsis the science of cognitive enhancement,” the company states. “So, whether it’s happiness, intelligence, creativity, focus, memory, energy, stress reduction, or self-control, our research & development team is working on new formulas to make your life better.” The Happy Co. is a leading producer and distributor of nootropic, functional beverage products with a focus on health and wellness. The company launched in February 2021 with an established foundation of distinctive nootropic products. The company offers functional beverages, capsules, patches and creams that elevate mood, boost energy, reduce stress, enhance sleep, increase muscles, minimize fat and tighten skin. Happy Company products are nootropics, or nutraceutical formulations derived from food sources that provide health benefits above and beyond basic nutritional value. A publicly traded company specializing in the direct-sales sector, Sharing Services Global Corporation is dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies. The Sharing Services combined platform leverages the capabilities and expertise of various companies that market and sell products direct to the consumer. Its primary division includes Elevacity U.S. LLC, the parent company of the Happy Co. and a sales and marketing company based on utilization of independent contractors as the sales force. For more information, visit the company’s websites at www.SHRGInc.com and www.TheHappyCo.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Christopher Thurber brings impressive expertise in software engineering, machine learning, IT and security analysis
• Thurber’s primary responsibility will be working on PRPI’s proprietary AutoGrafic Software System
• Thurber’s depth of experience is particularly valuable as the company just completed acquisition of the AutoGrafic Software System earlier this year

Perpetual Industries (OTC: PRPI) has announced that Christopher Thurber, an enterprise-level data specialist, has joined the company as its newest data scientist (https://ibn.fm/3EHLH). Thurber brings with him impressive expertise in software engineering, machine learning, IT and security analysis. “We’re very excited to have Chris on board,” said Perpetual Industries CEO Brent Bedford. “His depth of technical knowledge and analytical expertise will complement our growing team of seasoned developers.” Bedford noted that Thurber’s primary responsibility will be working on PRPI’s proprietary AutoGrafic Software System as well as supporting the company’s development of machine learning (“ML”), data analysis and internet of things (“IoT”) as it relates to PRPI’s XYO Enhanced Washing Machine and the WindSilo Vertical Axis Wind Turbine (“VAWT”) projects. Before joining Perpetual Industries, Thurber gained invaluable experience and expertise as a senior IT specialist and data scientist. In those roles, he was responsible for managing large amounts of enterprise-level data, building SQL solutions, deploying in-production machine learning models and implementing new algorithms to optimize codebases. The company noted that Thurber enjoys using data to solve difficult problems and has been an avid programmer for most of his life using coding languages such as Python, Rust, Javascript, Ruby, Go and C. Thurber’s depth of experience is particularly valuable as the company just completed its acquisition of the AutoGrafic Software System earlier this year (https://ibn.fm/QM8Mn). Much of Thurber’s attention will be focused on the software as a service (“SaaS”) and social application, which is designed to use cutting-edge technology to host a myriad of aspects for automotive promotion and preservation. At the time of the acquisition, Perpetual CEO Brent Bedford observed that “this acquisition provides another foundational piece in our quickly expanding blockchain division and, in addition to outstanding software, augments our team with some truly exceptional talent. It will also greatly benefit Worldwide Auctioneers, our newly acquired wholly owned subsidiary, by bringing much-needed new technology and innovation to their customers and the collector car industry at large.” Company officials also noted at the time that they planned on creating a new division for AutoGrafic and expanding team members working with the software and its developers, Travis LaVine and Jason Stoller. “The resulting combined expertise of these visionaries and the company will elevate the platform, bringing it to its full potential,” the acquisition statement noted. Plans for the software included a mobile app, loyalty program, tokenization on the blockchain and a full suite of other multidimensional features. Thurber will undoubtedly become an invaluable member of this PRPI team as he works alongside others who are devoted to the realizing the full potential of the AutoGrafic software system. Perpetual Industries is an incubator for the development of new and innovative energy-efficient technologies. The company’s mission is to “perpetuate industry” by bringing value-added technologies to market. The company is expanding its expertise and knowledge of energy-efficient technology by developing low-cost, green-energy-powered solutions for a variety of industries while continuing its research, development and commercialization of the XYO Technology in key applications. For more information, visit the company’s website at www.PerpetualIndustries.com. NOTE TO INVESTORS: The latest news and updates relating to PRPI are available in the company’s newsroom at https://ibn.fm/PRPI

• Lexaria has progressed significantly in evidencing that its patented DehydraTECH(TM) drug delivery technology can sufficiently improve the usable fraction of known antiviral drugs that reach the bloodstream
• According to a Newsfile Corp. article, this technology can be applied to rendering treatments for HIV/AIDS and other infectious diseases more effective
• The company also released partial results from a human clinical study evaluating DehydraTECH-processed CBD for potential application against hypertension, which evidenced a rapid and sustained drop in blood pressure
• Growing hypertension and antiviral therapeutics market represent a potential win for Lexaria

In July, Lexaria Bioscience (NASDAQ: LEXX), a drug delivery technology developer, issued several key announcements that, in addition to highlighting the progress made in advancing its patented DehydraTECH(TM) drug delivery technology, form the basis of analysis in a recent Newsfile Corp. article (https://ibn.fm/1BOgg). On July 22, the Kelowna-based global innovator reviewed its successful 2021 antiviral drug program. With diseases caused by viruses, including HIV/AIDS, influenza, and, more recently, COVID-19, having made the demand and need for effective antiviral drugs via oral delivery that are available to all more profound than ever before, Lexaria has made strides. The company has progressed significantly in evidencing that DehydraTECH can sufficiently enhance the usable fraction of known antiviral drugs that reach the bloodstream to safely and more effectively do what they are designed to accomplish. Still, it continues to evaluate the data generated from the program (https://ibn.fm/MQIDe). According to the Newsfile article, the antivirals represent a much broader market for DehydraTECH, especially currently, because in response to COVID-19, they “are having a moment.” Even so, “the same technology can be applied to rendering treatments for AIDS and other infectious diseases more effective. Antihistamines and anti-inflammatory drugs, as well as such therapeutics as remdesivir, have all been shown to be enhanced by DehydraTECH in animal studies,” the article notes. Lexaria is likely to benefit from the projected growth in the global antiviral therapeutics market, which is expected to surge to $67.76 billion in 2026 from $51.26 billion in 2020, representing a 4.76% CAGR. Analysts at Mordor Intelligence peg this growth on robust R&D investment in antiviral drugs by public and private companies (https://ibn.fm/NbkIA). Notably, the antiviral program is just one of several others Lexaria is focusing on at present. Another applied R&D program, which also featured prominently in the Newsfile article, is hypertension. On July 29, the company released partial results from a human clinical study, HYPER-H21-1, evaluating DehydraTECH-processed cannabidiol (“CBD”) for potential application against hypertension (https://nnw.fm/9WvGd). (https://cnw.fm/rYTu4). (https://ibn.fm/fmGyE). The study revealed a rapid and sustained drop in blood pressure with DehydraTECH-processed CBD and was most pronounced within the first 10 to 50 minutes of the study. This evidence reinforced the company’s pre-existing findings and further demonstrated that its drug delivery technology offers superior performance over generic CBD controls (https://ibn.fm/eYP1p). “That CBD would be among the first use cases for such a platform as DehydraTECH makes sense,” reads the Newsfile article, “FDA-approved for pediatric seizure purposes since 2018, it has gained a great deal of traction over a short period of time. While its most closely identified delivery vector is hemp cigarettes, these can damage lungs as much as pills can damage livers.” The article further notes that hypertension represents a new market for CBD and a potential huge win for Lexaria. Valued at $27.8 billion in 2018, the antihypertensive drug market is expected to grow at a CAGR of about 2% from 2019 to 2027 (https://ibn.fm/eMoJz). On July 28, Lexaria announced that DehydraTECH is available for sale in more than 7,000 stores across the US, in what CEO Chris Bunka noted was an indication that the delivery technology is enabling increased market share and sales growth for its expanding list of corporate clients (https://ibn.fm/U4ws7). The article also highlights Lexaria’s financial information. “Its balance sheet is clean, but that is in large part due to Lexaria’s ability to raise money on financial markets. Earnings are not what one would hope for, and yet the market cap is roughly 10x assets, suggesting high confidence in management,” it concludes. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Hearing loss affects a considerable number of older adults; one-third of 65-year-olds and half of 75-year-olds suffer from some hearing impairment
• In an increasingly aging society, this could quickly become a public health problem as it is associated with high societal and healthcare costs
• INND continues to disrupt hearing healthcare; committed to providing game-changing hearing technology in a potentially growing market for hearing aids
• InnerScope’s launches its hearing aids on FSAstore.com, HSAstore.com, and WellDeservedHealth.com consumers enrolled in flexible spending accounts (“FSA”), health saving accounts (“HSA”), and employers’ health incentive programs

InnerScope Hearing Technologies (OTC: INND), a hearing health technology company that manufactures, develops, distributes, and sells innovative hearing health-related products, solutions, and treatments, appears poised to enhance the quality of life for around 70 million Americans suffering from hearing-related problems and to contribute to the improvement of their mental and physical well-being. Age-related hearing loss — also called presbycusis — is a common condition in older adults. It is estimated that about one-third of 65-year-olds and half of 75-year-olds suffer from some hearing loss. The condition considerably impacts the quality of life of affected people, hindering their ability to communicate with their environment and function in society (https://ibn.fm/N7eXz). With such a negative impact on their social lives, it comes as no surprise that the disease is linked to a higher incidence of depression, anxiety, and dementia. A National Institute on Deafness and Other Communication Disorders study revealed that more than 11% of adults with hearing loss also suffer from depression, compared with only 5% of the general population (https://ibn.fm/LmcgE). Hearing loss also coexists with higher levels of anxiety and is associated with higher rates of dementia, especially when coupled with visual impairment (https://ibn.fm/phr0L). It is also strongly associated with higher cognitive and physical impairment. Given numerous associated health risks, hearing loss burdens affected individuals, their families, and the economy as it leads to higher healthcare costs. In an increasingly aging society, this is becoming a critical public health concern. Despite a high prevalence of hearing loss, only about one-fifth of people who could benefit from a hearing aid seek intervention, and even fewer take advantage of technology that might help them. This means that there is a large population of patients living with unmet healthcare needs (https://ibn.fm/Uv72J). This is where InnerScope can offer solutions that can change the lives of millions of Americans suffering from hearing loss. As a direct-to-consumer manufacturer, distributor, and retailer of FDA-registered Bluetooth app-controlled self-adjusting hearing aids and personal sound amplifiers products, the Company is poised to empower consumers to take control of their hearing care. InnerScope recently launched its hearing aids and related hearing products on FSAstore.com, HSAstore.com, and WellDeservedHealth.com for the 70 million consumers enrolled in flexible spending accounts (“FSA”), health saving accounts (“HSA”), and employers’ health incentive programs.  InnerScope partnered with the online retailer and industry leader in the U.S. tax-free healthcare market. Moreover, InnerScope’s hearing aids and related hearing products qualify as eligible products for FSA and HSA users and is the only company on the retailers’ websites to offer hearing aids. The Company is committed to bringing hearing healthcare to customers’ homes by providing top-quality, affordable access to hearing aids without the need to see a hearing professional or go to a hearing care clinic. The Company continues to revolutionize the hearing healthcare landscape despite being in the retail hearing device business for over 70 years. By delivering the same quality of medical-grade hearing technology and the same level of expert support at a fraction of the cost of traditional channels, InnerScope strives to remove barriers to hearing healthcare for millions of people suffering from hearing impairment. For more information, visit the company’s website at www.INND.com and the company’s e-commerce website: www.MyHearIQ.com. NOTE TO INVESTORS: The latest news and updates relating to INND are available in the company’s newsroom at https://ibn.fm/INND

• Brain Scientific focused on leveraging AI and ML to detect neurological diseases, aims to create comprehensive database of brain biomarkers to increase diagnosis accuracy
• Brain Scientific positioned to disrupt EEG market with FDA-cleared patented products that provide cost-effective brain imaging in any setting
• Current global EEG device market estimated at $956.1 million with CAGR of 8.7% from 2019 to 2026, expected to reach $1.6 billion by 2026

With more industries embracing artificial intelligence (“AI”) and machine learning (“ML”) than ever before, Brain Scientific (OTCQB: BRSF), a commercial-stage healthcare company, is ahead of the curve in the neurology market with its development of cost-effective next-generation medical devices and software that aim to leverage AI and ML to improve brain diagnostics in the rapidly growing electroencephalogram (“EEG”) market. AI generally refers to human-like intelligence capabilities demonstrated by computers, and ML is a subset of AI that refers to algorithms that “learn” through the use of data. Together, they are being used in healthcare to analyze data sets and make treatment predictions that aim to produce better health outcomes. With a similar goal, BRSF aims to leverage AI and ML to improve diagnostic capability with a database of brain biomarkers that collect data on both normal and abnormal brain information. Brain Scientific’s use of AI and ML is part of its overall market penetration strategy that includes the development of its patented FDA-cleared NeuroCap(TM) and NeuroEEG(TM) devices. With 22 electrodes and 19 active EEG channels, the NeuroCap — a disposable pre-gelled EEG headset — can be used to record EEGs in nearly any setting. The NeuroCap is complimented by the NeuroEEG — a portable clinical-grade wireless EEG amplifier that acquires, records, displays and transmits electrical brain activity. Cost-effective, portable, and easily accessible, both devices together are positioned to profoundly shift the market by offering practitioners an affordable way to diagnose brain-related disorders in a range of locations, including remote clinical research labs, neurology clinics, urgent care clinics, emergency departments, ICUs, assisted living facilities, and nursing homes. According to Grandview Research, the current global EEG device market was estimated at $956.1 million in 2020 and is expected to reach $1.6 billion revenue by 2026 with an anticipated CAGR of 8.7% between 2019-2026 (https://ibn.fm/AYsYg). Along with roughly 150 million people diagnosed with epilepsy, dementia and Alzheimer’s disease globally, BRSF is strongly positioned to capture a significant market share of the demand for low-cost imaging devices across the world. Headquartered in New York, Brain Scientific and its wholly owned subsidiary MemoryMD Inc. were founded in 2015 and went public in 2018. With a focus on developing innovative medical devices and software that disrupt the brain diagnostics market, BRSF is poised to take center stage with solutions that enable medical professionals to cost-effectively diagnose patients with consistency, efficiency and accuracy in virtually any setting. For more information, visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Microdose Psychedelic Insights will host the upcoming DMT Conference on September 9-10th, 2021
• Part of a series of deep dive events looking into various psychoactive and psychedelic substances, the DMT conference will examine the potential of DMT within today’s society
• The conference will play host to a number of keynote presentations and discussions delivered by some of the industry’s leading thinkers and innovators

Microdose Psychedelic Insights (“Microdose”) is set to host their virtual DMT Conference on September 9-10th, 2021. The event will serve as a deep dive into the dynamic field of DMT therapeutics, featuring a number of expert panels and engaging discussions focused on the potential of Dimethyltryptamine (“DMT”) in today’s society. Microdose Psychedelic Insights, a cutting-edge media company focused around promoting content, financial analysis, and engaging events focused around the psychedelics industry, have gained renown for their unique vision towards shifting the global perception around psychedelic medicine through a series of innovative events. Forming part of Microdose’s Molecular Masterclasses conference series, which has previously featured events looking into Ketamine, MDMA, Ibogaine and Functional Mushrooms, the DMT Conference will seek to introduce investors and attendees to a curated group of CEO’s, corporate leaders and scientists who will seek to delve deeper into the intricacies surrounding the DMT universe. This year’s conference will be inaugurated by an introductory talk, delivered by Patrick Moher, CEO of Microdose Psychedelic Insights. The conference will subsequently play host to a series of hour long presentations and keynote addresses exploring different aspects within the psychedelic industry and DMT in particular. Topics which will be covered will include, “Addiction and DMT” delivered by Entheon Biomedical; “Non-Neuropsychiatric Uses for DMT” by PharmaDrug Inc, “DMT Drug Development” from Small Pharma INC; and a keynote presentation by Algernon Pharmaceuticals entitled “DMT – New Hope for Healing the Brain After a Stroke” among various others. In addition, the conference will also feature several other expert speakers, including the likes of Christopher Timmermann-Slater, Andrew Hegle, Paul Van Slyke, Daniel Cohen, Christopher Moreau, Jackie von Salm, Carol Routledge, Brian Jahns, Natan Ponieman, Andrew Hegle Paul Van Slyke, Christopher Timmermann-Slater Peter Rands, Graham Pechenik David Wood, Ruth Chun, Hadas Alterman Rick Strassman MD, Timothy Ko, Brian Jahns, Crystal Carson, Joël Brierre, Max Montrose, Tricia Eastman, Rak Razam, Victoria Wueschner. Microdose’s DMT Conference will be presented in partnership with Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1), a biotechnology company focused on developing psychedelic medicines to treat addiction, Small Pharma (TSX.V: DMT) a neuropharmaceutical company taking a novel approach to depression drug development, Algernon Pharmaceuticals Inc. (CSE: AGN) a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis (“IPF”) & chronic cough, and COVID-19, and Pharmadrug, a Biotech Company Focused on the R&D of Natural Based Medicines. Additional information about the DMT Conference, as well as details for registration can be found at the DMT Conference website at https://microdose.buzz/pnwmm About Microdose Psychedelic Insights: Microdose Psychedelic Insights is your guide to the psychedelic medicine industry. With a vision to shift the world’s perception of psychedelic medicine, we distribute and create the most compelling content, financial analysis, engaging events, and groundbreaking education to drive the psychedelics industry to the forefront of modern medicine. About Molecular Masterclasses: Our Molecular Masterclasses are a speaker series designed for deep dives into the world’s favourite psychoactive and psychedelic substances. Each event will explore one drug, and feature a curated group of industry experts and thought leaders from around the world. Contact: Microdose Psychedelic Insights kristina@microdose.buzz Media Contact:  InvestorBrandNetwork (“IBN”) Los Angeles, California www.InvestorBrandNetwork.com

• On August 25, FingerMotion held a conference call in which it provided updates on the progress of its Sapientus division, application to uplist to the NASDAQ, and more
• Hosted by FingerMotion CEO Martin Shen, the corporate update also included a review of the Q1 2022 results, which marked the fourth consecutive quarter of record revenue
• FingerMotion received its first comment letter from NASDAQ, to which it responded promptly and efficiently
• The company, in collaboration with its partners, has begun translating products under the Sapientus division into an actual operational pilot
• FNGR will hold an AGM in November

In July last year, FingerMotion (OTCQX: FNGR) launched Sapientus, its Big Data Insights arm and third operational division, built to deliver data-driven insights and solutions for companies and businesses in the insurance and financial services sectors (https://ibn.fm/fMJF6). Since then, the division has grown in many ways. For instance, it witnessed two consecutive quarters of revenue generation during Q4 2021 and Q1 2022 and quarter-over-quarter revenue growth during the latter reporting period (https://ibn.fm/iPz2A). Additionally, earlier this year, FNGR reported an agreement between Sapientus and Pacific Life Re-Insurance to provide cutting-edge behavioral risk analytics for the insurance company (https://ibn.fm/xSnGM). So, what further progress has the division made since then? In an August 25 conference call, whose recording is available on the company’s website (https://ibn.fm/BnQra), FingerMotion CEO Martin Shen sought to answer this question as part of a corporate update aimed at informing shareholders and the general public about FNGR’s progress thus far and outlook for the future. Included in the August 25 update were the strides the Sapientus division has made, progress on the application to uplist on NASDAQ, a review of the Q1 2022 results, and general announcements. Firstly, Martin discussed the Q1 2022 results for the three months ended May 31, 2021. Pleased with all facets of the business as all facets were growing tremendously, he observed that Q1 2022 represented the company’s fourth consecutive quarter of record revenue, having recorded revenue of $6 million. According to Shen, FingerMotion is optimistic that it will be a profitable business “fairly soon” and has set its sights on higher-margin verticals. Regarding its uplist application to the Nasdaq Capital Market, FNGR focused on “getting it right the first time” by meeting most of the objective criteria and parameters. “To further bolster our own confidence, we received our first comment letter from Nasdaq fairly quickly, meaning we had met most of the parameters in the first place,” Shen added. The company brought in an independent advisory firm, which collaborated with its in-house counsel to issue an efficient, fast response to the comment letter. Shen was, however, quick to caution viewers on the need to keep their optimism in check, given that several other hurdles are yet to be surmounted. Still, he expressed his pride in his team’s work so far, further noting the company’s commitment to promptly and efficiently answering all questions NASDAQ’s examiners send. “The launch of Sapietus marked a significant milestone for our journey because we moved away from being a top-up company to this dynamic technology solution provider and allowed us to expand our company and business into insurance and then the wider financial industry in general,” Shen described Sapientus. He continued, “Our distinctive edge and what we do as Sapientus is our ability to integrate all these publicly available data into these proprietary risk matrices with behavioral indicators derived from event-driven or even contextual-based information.” Shen pointed out that Sapientus, which prioritizes privacy protection, uses advanced algorithms to generate distributional statistics and categorical variables agnostic to individual identity. Crucially, though, the data only contains demographic markers. By providing the desired level of customer understanding through behavioral analytics, Sapientus aims to supply actionable intelligence and facilitate the efficient delivery of services to various players within the insurance industry. Working with partners such as Pacific Life Re-Insurance, FingerMotion has begun translating its Sapientus-based products into an actual operational pilot that benefits the service providers and customers alike. For insurance companies, it will provide value, enhance efficiencies, and lower the cost-of-service delivery. At the same time, it will eliminate existing pain points insurance customers had. Shen also outlined future development plans for the Sapientus division. Lastly, FingerMotion announced its AGM scheduled for November and will provide additional updates on this in due course. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

Date: September 10-12, 2021 Exhibit Hall Hours Friday, September 10     11:00 AM – 5:00 PM Saturday, September 11    11:00 AM – 5:00 PM Sunday, September 12      10:00 AM – 4:00 PM Hynes Convention Center, Boston MA Onsite Box Office opens at 9:00 am each day Cannabis cultivators, dealers, businesses, and enthusiasts are invited to attend the NECANN, on September 10-12, 2021. Operating since 2014, NECANN events are touted as one of the largest cannabis events on the east coast. The NECANN events attract a huge number of Hemp, MMJ and Cannabis industry professionals in the Northeast to their annual Boston Cannabis Convention. These events are the home base for the New England cannabis industry. The New England Cannabis Convention in Boston offering robust networking, communication and business opportunity for cannabis growers, consumers and business cultivators across the region. The 2019 event was attended by over 9,000 people, which is expected to cross the 10,000 marks this year. With recreational marijuana legal in Massachusetts, the crowds at the event have grown phenomenally. The event is attended by industry stalwarts, thinkers and cannabis leaders who share their insights, business ideas and discuss the future trends of this growing industry. The NECANN offers a wonderful platform to small industries, startups and new cannabis growers and dealers to discover new business prospects and establish ties with eminent cannabis companies and investors. They also learn the latest trends and technologies that can be employed in the cultivation and supply of the cannabis crop. The event offers knowledge and information regarding the latest regulation and taxation laws that are applied to marijuana cultivation and the tools and requisites these cultivators require to get started. They will also get educated about the environmental concerns surrounding the harmful effects of indoor cultivation and how government schemes are necessary to encourage environmental sustainability and energy performance in cannabis cultivation techniques. The event also showcases the Certified Massachusetts Marijuana Responsible Vendor Training course, which is approved by the state of Massachusetts for cannabis dispensary agents and meets the responsible dispensing organization agent training requirements mandated. Attendees can register beforehand for this event as it requires a separate ticket. Small businesses and cultivators must attend this session to gain clarity on the Commonwealth’s cultivation regulations and understand the steps that growers and cannabis advocacy groups are taking to get more businesses up and bring more craft cannabis to patients and other adult consumers. For more details about the event, please visit https://necann.com/2020-boston-2/.